In this context, we have made a study on patient bone marrow specimens showing the expression rates of PD-1 and PD-L2 in various hematologic malignancies; however, we could not find a meaningful evidence that these markers have an impact on prognosis. Here, PDCD1LG2 is linked to hematologic disorder.